Nymox Pharmaceutical Release: BPH: A Major Challenge for Men’s Healthcare

July 10, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has developed an innovative new treatment for BPH, NX-1207, which has now entered Phase 3, the final stage of drug testing before applying for FDA approval.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase III